AFT Pharmaceuticals (NZSE:AFT) FFO


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
96 GF Score
Price NZ$3.68
GF Value NZ$4.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

NZSE:AFT
96GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.68 is trading 11.3% below its estimated GF Value™ of NZ$4.15. GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NZSE:AFT:

  • FFO:
  • GF Value™: NZ$4.15 vs. price of NZ$3.68 (11.3% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
96GF Score

Get the complete analysis for NZSE:AFT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.68
Price
NZ$4.15
GF Value